Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.60 |
| ▸ | FNTA | P49354 | 5/20 | 0.56 |
| ▸ | FNTB | P49356 | 5/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ECE1 | P42892 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9447263 | 0.93 | CTSC (0.67) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL28334124 | 0.93 | CTSC (0.67) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL2545492 | 0.93 | CTSC (0.67) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL30051862 | 0.93 | CTSC (0.60) | CTSCFNTAFNTBACEMEN1 | |
| SCHEMBL11228723 | 0.93 | CTSC (0.65) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL11228707 | 0.93 | CTSC (0.65) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL30051812 | 0.92 | CTSC (0.57) | CTSCACEMEN1KMT2AECE1 | |
| Hydrochloric Acid SCHEMBL11220807 | 0.92 | CTSC (0.64) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL30051770 | 0.92 | CTSC (0.65) | CTSCACEMEN1KMT2AECE1 | |
| SCHEMBL30051220 | 0.91 | CTSC (0.62) | CTSCACEMEN1KMT2AECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885FNTA 734/4885FNTB 479/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSC 37/4885FNTA 776/4885FNTB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.